Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 8/2015

Open Access 01-08-2015 | Review Article

Repurposing medicinal compounds for blood cancer treatment

Authors: Bronagh McCabe, Fabio Liberante, Ken I. Mills

Published in: Annals of Hematology | Issue 8/2015

Login to get access

Abstract

Drug development is being continuously scrutinised for its lack of productivity. Novel drug development is associated with high costs, high failure rates and lengthy development process. These downfalls combined with a huge demand in blood cancer for new therapeutic treatments have led many to consider the method of drug repurposing. Finding new therapeutic indications for already established drug substances is known as redirecting, repositioning, reprofiling, or repurposing of drugs. Off-patent and on-patent drugs can be screened for additional targets and new indications thus bringing them to clinical trials at a faster pace. This approach offers smaller research groups, such as those that are academic based, into the drug development industry. Drug repurposing can make use of previously published data concerning dosage, toxicology and mechanism of activity.
Literature
1.
Ashburn TT, Thor KB (2004) Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 3(8):673–683PubMedCrossRef
2.
DiMasi JA, Hansen RW, Grabowski HG (2003) The price of innovation: new estimates of drug development costs. J Health Econ 22(2):151–185PubMedCrossRef
3.
Report to the President of propelling innovation in drug discovery, development and evaluation. 2012. The President’s Council of Advisors on Science and Technology
4.
5.
U.S. Food and Drug Administration CfDEaR. Novel New Drugs 2014 Summary
6.
7.
8.
Kola I, Landis J (2004) Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3(8):711–715PubMedCrossRef
9.
Smith A, Howell D, Patmore R, Jack A, Roman E (2011) Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. Br J Cancer 105(11):1684–1692PubMedCentralPubMedCrossRef
10.
Jaffe ES, Harris NL, Stein H, Vardiman J (2001) World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARC
11.
Swerdlow SH, Campa E, Harris NL, Jaffe ES, Pileri SA, Stein H et al (2008) WHO classification of tumours of haematopoietic and lymphoid tissues. IARC, Lyon
12.
13.
14.
Pantziarka P, Bouche G, Meheus L, Sukhatme V, Sukhatme VP, Vikas P (2014) The Repurposing Drugs in Oncology (ReDO) project. Ecancermedicalscience 8:442PubMedCentralPubMedCrossRef
15.
Huang M, Shen A, Ding J, Geng M (2014) Molecularly targeted cancer therapy: some lessons from the past decade. Trends Pharmacol Sci 35(1):41–50PubMedCrossRef
16.
Li F, Zhao C, Wang L (2014) Molecular-targeted agents combination therapy for cancer: developments and potentials. Int J Cancer 134(6):1257–1269PubMedCrossRef
17.
Pantziarka P, Bouche G, Meheus L, Sukhatme V, Sukhatme VP (2014) Repurposing drugs in oncology (ReDO)-cimetidine as an anti-cancer agent. Ecancermedicalscience 8:485PubMedCentralPubMedCrossRef
18.
Pantziarka P, Bouche G, Meheus L, Sukhatme V, Sukhatme VP (2014) Repurposing Drugs in Oncology (ReDO)-mebendazole as an anti-cancer agent. Ecancermedicalscience 8:443PubMedCentralPubMedCrossRef
19.
Van Nuffel AM, Sukhatme V, Pantziarka P, Meheus L, Sukhatme VP, Bouche G (2015) Repurposing Drugs in Oncology (ReDO)-clarithromycin as an anti-cancer agent. Ecancermedicalscience 9:513PubMedCentralPubMed
20.
Huang R, Southall N, Wang Y, Yasgar A, Shinn P, Jadhav A et al (2011) The NCGC pharmaceutical collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics. Sci Transl Med 3(80):80ps16PubMedCentralPubMedCrossRef
21.
Thakkar KB, Billa G (2013) The concept of: generic drugs and patented drugs vs. brand name drugs and non-proprietary (generic) name drugs. Front Pharmacol 4:113PubMedCentralPubMed
22.
23.
24.
25.
Diggle GE (2001) Thalidomide: 40 years on. Int J Clin Pract 55(9):627–631PubMed
26.
Jin G, Wong ST (2014) Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines. Drug Discov Today 19(5):637–644PubMedCentralPubMedCrossRef
27.
Pfister DG (2012) Off-label use of oncology drugs: the need for more data and then some. J Clin Oncol 30(6):584–586PubMedCrossRef
28.
Stephen R, Knopf K, Reynolds MW, Luo W, Fraeman K (2009) Off-label use of oncology drugs in a community oncology EMR database. Value Health 12(3):A57CrossRef
29.
Swamidass SJ (2011) Mining small-molecule screens to repurpose drugs. Brief Bioinform 12(4):327–335PubMedCrossRef
30.
Jin G, Fu C, Zhao H, Cui K, Chang J, Wong ST (2012) A novel method of transcriptional response analysis to facilitate drug repositioning for cancer therapy. Cancer Res 72(1):33–44PubMedCentralPubMedCrossRef
31.
Kinnings SL, Liu N, Buchmeier N, Tonge PJ, Xie L, Bourne PE (2009) Drug discovery using chemical systems biology: repositioning the safe medicine Comtan to treat multi-drug and extensively drug resistant tuberculosis. PLoS Comput Biol 5(7):e1000423PubMedCentralPubMedCrossRef
32.
Blatt J, Corey SJ (2013) Drug repurposing in pediatrics and pediatric hematology oncology. Drug Discov Today 18(1–2):4–10PubMedCrossRef
33.
Qu XA, Rajpal DK (2012) Applications of connectivity map in drug discovery and development. Drug Discov Today 17(23–24):1289–1298PubMedCrossRef
34.
35.
Houghton PJ, Morton CL, Gorlick R, Lock RB, Carol H, Reynolds CP et al (2010) Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing Program. Mol Cancer Ther 9(1):101–112PubMedCentralPubMedCrossRef
36.
Heinrich MC, Joensuu H, Demetri GD, Corless CL, Apperley J, Fletcher JA et al (2008) Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases. Clin Cancer Res 14(9):2717–2725PubMedCrossRef
37.
38.
39.
Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P et al (1999) Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341(21):1565–1571PubMedCrossRef
40.
Dagher R, Cohen M, Williams G, Rothmann M, Gobburu J, Robbie G et al (2002) Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res 8(10):3034–3038PubMed
41.
Lassman AB, Pugh SL, Gilbert MR, Aldape KD, Geinoz S, Beumer JH et al (2015) Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627). Neuro Oncol
42.
Zhao H, Jin G, Cui K, Ren D, Liu T, Chen P et al (2013) Novel modeling of cancer cell signaling pathways enables systematic drug repositioning for distinct breast cancer metastases. Cancer Res 73(20):6149–6163PubMedCentralPubMedCrossRef
43.
44.
Xu K, Cote TR (2011) Database identifies FDA-approved drugs with potential to be repurposed for treatment of orphan diseases. Brief Bioinform 12(4):341–345PubMedCrossRef
45.
46.
Metadata
Title
Repurposing medicinal compounds for blood cancer treatment
Authors
Bronagh McCabe
Fabio Liberante
Ken I. Mills
Publication date
01-08-2015
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 8/2015
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-015-2412-1

Other articles of this Issue 8/2015

Annals of Hematology 8/2015 Go to the issue

Letter to the Editor

Antiphospholipid syndrome in a patient suffering from congenital dyserythropoietic anemia type III

Letter to the Editor

Is thrombin time too sensitive to dabigatran anticoagulation for clinical decision making in the setting of acute hemorrhage?

Letter to the Editor

Eosinophilic gastroenteritis after allogeneic bone marrow transplantation

Letter to the Editor

Fatal pulmonary hemorrhage after carfilzomib treatment in multiple myeloma

Original Article

Improved outcome of pediatric patients with acute megakaryoblastic leukemia in the AML-BFM 04 trial

Original Article

Mean corpuscular volume of control red blood cells determines the interpretation of eosin-5′-maleimide (EMA) test result in infants aged less than 6 months
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits